MIM
MRSN

Monashee Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Monashee Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,400
Closed -$1.39M – 110
2024
Q1 		$1.39M Buy
+12,400
New +$1.23M 0.16% 85
2020
Q3 		– Sell
-12,000
Closed -$7.02M – 225
2020
Q2 		$7.02M Buy
+12,000
New +$4.1M 1.05% 21
2017
Q3 		– Sell
-4,311
Closed -$1.51M – 107
2017
Q2 		$1.51M Buy
+4,311
New +$1.49M 0.64% 41

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Monashee Investment Management's MRSN Position: Q2 2024 in Review

Monashee Investment Management sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 12,400 shares — an estimated $1.39M sold.

Monashee Investment Management first reported a position in MRSN in Q2 2017 and held it in 3 quarters. The position peaked at $7.02M in Q2 2020. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Monashee Investment Management reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 12,400 Mersana Therapeutics shares in Q2 2024, an estimated $1.39M.
  • Monashee Investment Management first reported a position in Mersana Therapeutics in Q2 2017 and held it in 3 quarters.
  • Monashee Investment Management's Mersana Therapeutics position peaked at $7.02M in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.